Research programme: ion channel modulators - Vertex Pharmaceuticals

Drug Profile

Research programme: ion channel modulators - Vertex Pharmaceuticals

Alternative Names: VX-409

Latest Information Update: 20 Apr 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Vertex Pharmaceuticals
  • Class
  • Mechanism of Action Ion channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Pain

Most Recent Events

  • 24 Jul 2007 Preclinical development is ongoing
  • 14 Dec 2005 VX 409 has been licensed to GlaxoSmithKline worldwide for the treatment of pain
  • 03 Feb 2004 Preclinical trials in Pain in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top